5-Amino-1-methylquinolinium · NNMT Inhibitor
A small-molecule NNMT (Nicotinamide N-Methyltransferase) inhibitor that upregulates NAD+ availability and activates cellular energy pathways. Studied for fat loss, metabolic optimization, and lean body mass preservation — available in convenient oral capsule form.
Physician review required · Ships in 48h after approval · All 50 states
5-Amino-1MQ (5-Amino-1-methylquinolinium) is a cell-permeable small molecule designed to inhibit NNMT — an enzyme that consumes SAM (S-adenosylmethionine) and reduces the availability of NAD+ in fat and other metabolic tissues. By blocking NNMT, 5-Amino-1MQ allows NAD+ levels to rise, activating downstream energy-sensing pathways like SIRT1 and AMPK.
In preclinical studies, NNMT inhibition with 5-Amino-1MQ resulted in significant reductions in fat mass without changes in lean mass — suggesting a highly selective metabolic effect. The compound is taken orally as a capsule, offering a practical alternative for those seeking metabolic support without injections.
Unlike stimulant-based fat burners, 5-Amino-1MQ works at the cellular level by restoring metabolic enzyme activity rather than artificially elevating heart rate or suppressing appetite. This makes it of particular interest for body composition optimization and long-term metabolic wellness.
NNMT (Nicotinamide N-Methyltransferase) is an enzyme highly expressed in fat tissue that consumes SAM and converts nicotinamide into 1-methylnicotinamide — reducing NAD+ availability. Elevated NNMT activity is associated with obesity and metabolic dysfunction. By inhibiting NNMT, 5-Amino-1MQ restores the pool of NAD+ and SAM available for energy metabolism, driving a cascade of cellular metabolic improvements.
The rise in NAD+ from NNMT inhibition activates SIRT1 (a longevity-associated deacetylase) and AMPK (the cellular energy sensor). These pathways collectively increase mitochondrial biogenesis, enhance fatty acid oxidation, and promote a shift toward fat burning over fat storage. Preclinical research has shown measurable reductions in fat cell size and total adipose mass in animal models treated with 5-Amino-1MQ.
One of the most clinically interesting findings from 5-Amino-1MQ research is its apparent selectivity — fat mass decreases while lean mass is preserved or improved. This is a meaningful distinction from traditional caloric restriction approaches, which often reduce both. For individuals focused on body composition rather than just weight loss, this selectivity makes 5-Amino-1MQ a compelling protocol element.
5-Amino-1MQ is delivered in oral capsule form — making it one of the most straightforward protocols in the BRAVO1 lineup. Dosing frequency and duration are determined through the physician review process based on your metabolic goals, current health status, and any concurrent protocols. No injections required.
View certificate of analysis and batch testing for 5-Amino-1MQ.
Start the physician review process for 5-Amino-1MQ. Ships within 48 hours of approval to all 50 states.
Start Physician Review →Lab documents for 5-Amino-1MQ will appear here once uploaded via the Admin Dashboard.
This website is intended for educational and informational purposes only. Products and services are subject to physician review and approval. Information provided is not medical advice. These statements have not been evaluated by the FDA.